Close

Valeant Pharmaceuticals To Participate At The UBS Global Healthcare Conference

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Valeant Pharmaceuticals International, Inc. announced that Mr. Joseph Papa, Chairman and Chief Executive Officer, will participate at the UBS Global Healthcare Conference to be held at the Grand Hyatt Hotel in New York City on Monday, May 23, 2016 at 8:30 a.m. ET.

A live webcast and audio archive of the event will be available on Valeant’s corporate website on the “Investor Relations” page, under the “Events and Presentations” tab and via this URL:http://ir.valeant.com/events-and-presentations.

Participants are encouraged to allow approximately five to ten minutes prior to the start time to visit the site and download any streaming media software needed to listen to the event.

About Valeant
Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:

Laurie W. Little                                              
949-461-6002                                                 
laurie.little@valeant.com
 
 
Elif McDonald
905-695-7607
kiau@novonordisk.com

Media:
Renée Soto

or

Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back